ClinicalTrials.gg
RecruitingNCT07938723Updated Nov 16, 2026

The Incidence and Clinical Characteristics of Infantile Hemangiomas

An observational study in Infantile Hemangioma (IH), sponsored by West China Hospital. Recruiting at 3 sites in China. Open to participants aged 0 Days to 7 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by West China Hospital · Observational

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3
Ages
0 Days to 7 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Hemangioma, Capillary with a site in China — 6 open to participants now, 7 under way, 1 of them phase 3. Hemangioma, Capillary · China.

Started
2024
with 1 other
Observational
7 of 12
5 open now
Registered
11th of 12
by date
Lead sponsor
8 of 12
West China Hospital

Among the 12 studies in Hemangioma, Capillary with a site in China, this one is one of 2 that started in 2024, is one of 7 observational ones, and was the 11th registered.

Hemangioma, Capillary

35 studies on the registry are indexed under Hemangioma, Capillary; 6 are open to participants now.

Browse Hemangioma, Capillary studies →

Open to participants now

6 of the 12 studies in Hemangioma, Capillary with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 3 Hemangioma, Capillary studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 0 Days to 7 Days · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Hemangioma, Capillary with a site in China, or all of them as a file.
02

Study summary

This study will follow babies born at three hospitals in China during their first year of life. The study will measure how often babies are diagnosed with infantile hemangioma, a growth of blood vessels in the skin that often appears in early infancy. The study team will record the age at diagnosis, the location and size of the hemangioma, and its clinical appearance. Babies with and without a hemangioma at the first examination can participate. Clinical care will follow usual practice.

Read the detailed description

This is a prospective, multicenter observational birth cohort study. At each of three participating hospitals, live-born infants will be screened using delivery records. All eligible infants will be invited consecutively during the recruitment period. Enrollment and a baseline skin assessment will take place within seven days of birth after a parent or legal guardian provides written informed consent.

Follow-up assessments are planned at 1 and 3 months of chronological age. The study team will also capture diagnoses documented between scheduled assessments. Trained study clinicians will use the same clinical criteria at all centers, with specialist review of uncertain cases. Suspected precursor lesions will be recorded at baseline and followed to establish the diagnosis. Clinicians will distinguish infantile hemangiomas from congenital hemangiomas and vascular malformations.

The primary analysis will include infants with an assessable baseline examination and without definite cutaneous infantile hemangioma at that examination. Secondary analyses will report the baseline prevalence and the overall proportion diagnosed by 3 months of age, including infants diagnosed at baseline. Clinical characteristics will be recorded at the first confirmed diagnosis. When several lesions are present, the lesion with the greatest documented diameter at diagnosis will be the index lesion for site, depth, morphology, and size.

Post-baseline cumulative incidence will be estimated on the chronological age scale with entry at the baseline examination and reported with a 95% confidence interval. Death before diagnosis will be treated as a competing event. Infants lost to follow-up will be censored at the last assessment at which their disease status could be determined. Clinical management will follow usual care.

03

Conditions studied

  • Infantile Hemangioma (IH)

Browse trials for

Keywords

  • Infantile Hemangioma, Cutaneous Hemangioma, Incidence, Birth Cohort, Epidemiology, Infants
04

Who can participate

Ages eligible
0 Days to 7 Days
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Live-born infants delivered at any of the three participating hospitals during the recruitment period. Eligible infants will be invited consecutively from hospital delivery records, regardless of gestational age, sex, or baseline infantile hemangioma status.

Eligibility criteria

Inclusion Criteria:

  • Live-born at one of the three participating hospitals during the recruitment period.
  • Aged 0 to 7 days at enrollment.
  • Written provided by a parent or legal guardian. Exclusion Criteria
  • Previously enrolled in this study at any participating center.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3 participants (estimated)
Target follow-up
3 Months
Patient registry
Yes

Groups and cohorts

  • Birth Cohort

    Live-born infants enrolled within seven days of birth at any of the three participating hospitals and followed through 3 months of chronological age.

06

What researchers measure

Primary outcomes

  1. Post-baseline Cumulative Incidence of Cutaneous Infantile Hemangioma by 3 Months of Age

    Estimated percentage of infants with an assessable baseline examination and no definite cutaneous infantile hemangioma at that examination who receive a first clinician-confirmed diagnosis by 3 months of age. Each affected infant is counted once. Death before diagnosis is treated as a competing event. Infants lost to follow-up are censored at the last assessment with ascertainable disease status.

    Time frame: From the baseline newborn assessment (within 7 days of birth) through 3months of chronological age.

Secondary outcomes

  1. Prevalence of Definite Cutaneous Infantile Hemangioma at Baseline

    Percentage of infants with an assessable baseline examination who have definite cutaneous infantile hemangioma at that examinatio

    Time frame: Baseline assessment, within 7 days of birth.

Other outcomes

  1. Anatomic Site of the Index Lesion

    Number and percentage of affected infants by the anatomic site of the index lesion (head and neck, trunk, extremities, diaper area, or other)

    Time frame: At first confirmed diagnosis, through 3 months of age.

07

Study locations

3 of 3 sites recruiting
  • Leshan Maternal and Child Health Hospital
    Chengdu, Sichuan 610066, China
    Recruiting
  • Guanghan Maternal and Child Health Hospital
    Luocheng, Sichuan 528754, China
    Recruiting
  • Santai Maternal and Child Health Hospital
    Santai, Sichuan 538774, China
    Recruiting
08

References and documents

Publications

  • Lin PF, Chen FC, Chen JY, Hu LH, Xie WJ, Liu TY, Guo SB, Lin XM, Liu XW, Ye XH, Li M, Jiang CH. Incidence and familial clustering of infantile haemangiomas: a multicentre study. J Eur Acad Dermatol Venereol. 2022 Sep;36(9):1641-1647. doi: 10.1111/jdv.18179. Epub 2022 May 9. PubMed 35470460 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Jun 2027, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartActual
Jun 1, 2024
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938723
Collaborators
Leshan Maternal and Child Health Care Hospital, Santai county maternal and Child Health Hospital, Guanghan Maternal and Child Health Hospital
Responsible party
Yi Ji (Doctor, West China Hospital) — Principal investigator
First posted
Nov 16, 2026
Start date
Jun 1, 2024
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Yi Ji, PhD
Contact
jijiyuanyuan@163.com
02885423453

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion